Sub-Domain 1 · Medicare Delivery Architecture

SD1 documents the Medicare delivery architecture governing the Medicare-eligible population in PA-3 — the federal entitlement framework under Social Security Act Title XVIII establishing Parts A (hospital insurance), B (medical insurance), C (Medicare Advantage MCO architecture), and D (prescription drug coverage); the federal regulatory framework conditioning provider participation, plan operations, and pharmacy delivery; Pennsylvania's regulatory overlay through PA Insurance Department MA and Medigap oversight; Pennsylvania's SHIP architecture (PA MEDI) and local navigation infrastructure through the Philadelphia Corporation for Aging; and the IRA Medicare Drug Price Negotiation Program whose first negotiated prices for 10 Part D drugs became effective January 1, 2026. The sub-domain analyzes Medicare delivery as a clinical-and-pharmacy-access architecture rather than a coverage-eligibility architecture. Coverage-eligibility, enrollment, and Low-Income Subsidy / Medicare Savings Program eligibility sit at D12 SD2 Medicaid & Health Coverage per Boundary 1; D21 SD1 owns provider participation, plan operations, pharmacy delivery, and the clinical pathway from enrollment forward.

Legal Architecture

Constitutional foundation

Medicare operates under Article I § 8 (Spending Clause; taxing-and-spending for the general welfare) and is administered through Title XVIII of the Social Security Act as amended. The 10th Amendment's reservation of police powers to the states grounds Pennsylvania's regulatory overlay on Medicare Advantage plan marketing, consumer protection, and Medicare Supplement (Medigap) underwriting rules. No constitutional tension at the program-design level; the federal-state interface that surfaces in Medicaid-expansion debates does not operate here because Medicare is a federal program operating directly with beneficiaries and providers rather than through state administration.

Federal statutory layer

Social Security Act Title XVIII (Medicare). 42 U.S.C. § 1395 et seq. The foundational statutory architecture; establishes Medicare Part A (hospital insurance), Part B (Supplementary Medical Insurance), Part C (Medicare Advantage), and Part D (Voluntary Prescription Drug Benefit Program). § 1395 establishes program framework; § 1395cc establishes provider agreements (the Conditions of Participation basis); § 1395w-21 et seq. establishes Part C Medicare Advantage (added by Balanced Budget Act of 1997; amended by Medicare Modernization Act of 2003); § 1395w-101 et seq. establishes Part D (MMA 2003); § 1395i et seq. establishes the Part A Trust Fund. Statutory stability: HIGH. The Medicare entitlement structure has been continuously authorized since 1965; statutory revisions have expanded scope rather than constricted entitlement. Administrative vulnerability: MODERATE. CMS rulemaking, coverage determinations, payment policies, and MA capitation rates are subject to executive-branch policy direction year-over-year.

Inflation Reduction Act of 2022 (P.L. 117-169) — Medicare Drug Price Negotiation Program. Adds Medicare Part E (Drug Price Negotiation) at § 1191 of the Social Security Act; authorizes the Secretary of HHS to negotiate prices for certain high-cost single-source drugs covered under Medicare Part D (and beginning 2028, Part B). Establishes an annual out-of-pocket cap for Part D drug costs — $2,100 in 2026, raised from $2,000 in 2025; eliminates the prior catastrophic-coverage cost-sharing; restructures Part D benefit phases; establishes inflation rebates for Part B and Part D drugs whose prices rise faster than inflation. Key provisions for SD1: § 1192 drug selection criteria (high-expenditure single-source drugs without generic / biosimilar competition; small-molecule drugs eligible after 7 years FDA approval, biologics after 11 years); § 1194 negotiation process; § 1193 coverage requirement (Part D plans must cover selected drugs at the negotiated maximum fair price). Statutory stability: HIGH-MODERATE. Statutorily anchored; political contestation continues. Trump Executive Order 14273 (April 15, 2025) maintained the program but directed modification proposals; the 2025 budget reconciliation law (OBBBA) broadened the orphan-drug exclusion affecting future drug-selection eligibility. Administrative vulnerability: MODERATE. CMS implementation guidance is subject to revision; the program's core statutory design is protected. Substantive architecture lives at D2 SD4 Chronic & Non-Communicable Disease; D21 SD1 owns the delivery-side operationalization.

Medicare Modernization Act of 2003 (P.L. 108-173). Restructured Part C as Medicare Advantage; created the Part D voluntary prescription-drug program; established the Medicare Savings Account framework; established competitive bidding for durable medical equipment. Statutory stability: HIGH. Administrative vulnerability: HIGH. Annual MA capitation rate-setting, star-rating methodology, prior-authorization regulation, and MA marketing rules carry substantial year-over-year administrative variation.

Emergency Medical Treatment and Active Labor Act (EMTALA). 42 U.S.C. § 1395dd. Conditions Medicare provider agreement on emergency-medical screening and stabilization for any individual presenting at a Medicare-participating hospital emergency department, regardless of payer. Statutory stability: HIGH. Administrative vulnerability: LOW-MODERATE. Statutorily and judicially enforced; agency discretion narrow.

Federal agency layer

Centers for Medicare & Medicaid Services (CMS). Operating division of HHS at 7500 Security Boulevard, Baltimore, MD 21244. Key sub-components for SD1: Center for Medicare (Medicare fee-for-service and Medicare Advantage coverage and payment policy); Center for Program Integrity (Medicare fraud, waste, and abuse oversight); CMS Office of Communications; Center for Drug and Health Plan Choice. The CMS Administrator (Mehmet Oz under the current administration) is a Senate-confirmed presidential appointee whose policy direction shapes the annual MA capitation rate announcement, the Part D Redesign Program Instructions, and IRA implementation guidance. Administrative vulnerability: HIGH. CMS's discretionary authority over rate-setting, coverage determinations, prior-authorization rules, and MA plan marketing is broad. The CY 2026 Part D Redesign Program Instructions issued April 7, 2025 set the $2,100 OOP threshold and other Part D structural parameters for 2026.

Department of Health and Human Services (HHS). Cabinet-level department; CMS's parent agency. Secretary Robert F. Kennedy Jr. The Secretary is the statutory negotiator under the IRA Drug Price Negotiation Program (delegated to CMS for operational implementation). EO 14273 on drug pricing operates at this level. Administrative vulnerability: HIGH.

Office of Inspector General (OIG, HHS). Independent oversight body; Medicare program integrity investigations; anchor healthcare-institution False Claims Act enforcement; Stark Law and Anti-Kickback Statute civil monetary penalties. Administrative vulnerability: MODERATE.

State statutory and agency layer

Pennsylvania Insurance Department (PID) — Medicare Advantage and Medicare Supplement regulation. PID regulates Medicare Advantage plans' state-licensing, marketing, and consumer-protection compliance under the PA Insurance Holding Companies Act (40 P.S. § 991.1401 et seq.) and the PA Unfair Insurance Practices Act (40 P.S. § 1171.1 et seq.); regulates Medigap underwriting and rate filings under 40 Pa. Code Chapter 89. Statewide Medigap rate adjustments effective July 1, 2025. Address: 1326 Strawberry Square, Harrisburg, PA 17120. Statutory stability: HIGH; administrative vulnerability: MODERATE. The PA Insurance Commissioner is a gubernatorial appointee; consumer-protection enforcement intensity varies.

Pennsylvania Department of Aging — PA MEDI Medicare Counseling Program (statewide SHIP). Operates the federally-designated State Health Insurance Assistance Program (SHIP) under SHIP grant authority (Older Americans Act Title VII; CMS contract); brand name PA MEDI; central counseling line 1-800-783-7067. Statutory stability: HIGH (SHIP statutory authority is durable). Administrative vulnerability: MODERATE. Annual SHIP grant funding levels and counselor capacity affect operational reach.

Pennsylvania Medicare Supplement Insurance Act (40 Pa. Code Ch. 89). Establishes Pennsylvania's Medigap consumer-protection framework operating in coordination with federal Medigap minimum standards (NAIC model law; 42 C.F.R. Part 403). Pennsylvania does not have a state-level Medigap birthday rule. Outside the initial 6-month Medigap Open Enrollment Period that follows Medicare Part B effective date, Pennsylvania Medigap insurers may apply medical underwriting unless a federal guaranteed-issue trigger (Medicare Advantage plan termination, employer retiree coverage termination) applies. Proposed legislation (Co-Sponsorship Memo 47375, 2025-2026 Regular Session) would create a 60-day annual birthday-rule switching window; the bill is not enacted as of May 2026. Pennsylvania also prohibits Medicare excess charges — providers may not charge above the Medicare-approved rate, irrespective of the federal 15% allowance for non-assignment providers. Statutory stability: HIGH; administrative vulnerability: LOW-MODERATE.

Livanta — Beneficiary and Family Centered Care Quality Improvement Organization (BFCC-QIO) for Pennsylvania. CMS-contracted independent organization; handles first-level Medicare appeals for hospital-discharge timing, skilled nursing facility termination, home health agency termination, and outpatient observation status; receives quality-of-care complaints from Medicare beneficiaries. Statutory stability: HIGH (BFCC-QIO function is mandated under 42 C.F.R. Part 475); administrative vulnerability: MODERATE (contractor identity rotates on CMS contract cycles).

Local statutory and agency layer

Philadelphia Corporation for Aging (PCA) — local APPRISE / PA MEDI counselor sponsor. PCA is the Philadelphia Area Agency on Aging under the Older Americans Act (42 U.S.C. § 3001 et seq.); operates the local network of PA MEDI counselors providing direct beneficiary navigation assistance for plan selection, claims questions, and dual-eligible coordination. Address: 642 N. Broad Street, Philadelphia, PA 19130. Statutory stability: HIGH; administrative vulnerability: MODERATE. Counselor availability is grant-funded and affects beneficiary outreach.

Cross-cutting structural features

Medicare delivery in PA-3 carries three structural features that recur across the constituent profiles in the next section.

First, the MA-to-Medigap asymmetry under Pennsylvania's regulatory architecture: federal MA enrollment-side flexibility (no medical underwriting at IEP) combined with Pennsylvania's underwriting-required Medigap return architecture (outside the one-time 6-month OEP and limited federal guaranteed-issue triggers) creates a one-way structural lock-in. The asymmetry is shared with most states but addressed in approximately 17 states through annual birthday-rule or anniversary-rule protections.

Second, the IRA drug-price negotiation delivery-side operationalization for the 10 selected Part D drugs effective January 1, 2026, with the $2,100 annual OOP cap as a structural ceiling regardless of the specific drug used. Round 2 (15 drugs) takes effect January 1, 2027; Round 3 selections in early 2026 were affected by OBBBA orphan-drug exclusion expansion.

Third, the federal-state-local pathway dependency: Original Medicare and Medicare Advantage are federal programs, but the PA-3 constituent's access to participating providers, Medigap supplementation, dual-eligible coordination, and Part D pharmacy networks depends on Pennsylvania's regulatory architecture and Philadelphia's local navigation infrastructure. PA MEDI counselor capacity is the operational bottleneck for beneficiary navigation.

Constituent profiles

These profiles illustrate the structural features above. The pathways are drawn from current law and verified Philadelphia County Medicare enrollment data applied to documented PA-3 conditions; the people are composites with no claim to identifiable individuals.

Profile 1: Dual-eligible Medicare beneficiary in North/Northwest Core

Constituent type: a North/Northwest Core PA-3 resident, aged 67, household income at or below 100% federal poverty level, recently transitioned from working-age HealthChoices Medicaid to Medicare-as-primary at age 65. The constituent has multiple chronic conditions documented at the population level for the North/Northwest Core (per the verified D2 SD3 cumulative-disadvantage finding) including elevated hypertension and diabetes prevalence; uses several prescription medications.

Pathway through the institutional system. At Medicare entitlement, the constituent received PA MEDI counseling through a Philadelphia Corporation for Aging counselor, which oriented to D-SNP options versus stand-alone Original Medicare with Medicare Savings Program assistance. The constituent enrolled in one of the 19 Philadelphia County D-SNPs for integrated Medicare-Medicaid coverage. The D-SNP covers Parts A, B, D and coordinates with the constituent's Community HealthChoices Medicaid plan for Medicaid-side cost-sharing and long-term services. Two of the IRA-negotiated drugs effective January 1, 2026 (for diabetes and cardiovascular management) sit on the D-SNP formulary at the negotiated maximum fair price under the IRA coverage requirement.

Outcome. Integrated Medicare-Medicaid coverage operates through D-SNP architecture; clinical pathway is operational for the chronic conditions managed; pharmacy access is structurally protected by the IRA coverage requirement; cost-sharing exposure is capped at $2,100 OOP for Part D drugs. Pathway breakdown risk concentrates at D-SNP / CHC provider-network mismatch — the documented coordination pattern where a provider accepts the Medicare-side coverage but not the secondary CHC plan.

Profile 2: Disabled adult Medicare beneficiary in West Philadelphia Core

Constituent type: a West Philadelphia Core PA-3 resident, aged 50, completed the SSDI 24-month wait in 2025, entered Medicare entitlement January 2026. Enrolled in HealthChoices Medicaid during the 24-month wait after meeting Medicaid disabled-adult eligibility following an earlier coverage gap during disability determination (cross-reference D12 SD2). Retained Medicaid as secondary at Medicare entitlement and transitioned to Community HealthChoices.

Pathway through the institutional system. Pre-Medicare provider relationships established under HealthChoices face continuity questions when Medicare becomes primary: providers must accept Medicare assignment to continue in-network status. Pennsylvania's excess-charge prohibition simplifies the cost calculus, but providers who do not accept Medicare entirely cannot continue billing under Medicare-primary architecture. Mental-health and substance-use providers (cross-reference D3 SD3) face higher discontinuity risk because behavioral-health Medicare participation rates are documented as systematically lower than primary-care participation. The constituent enrolled in a D-SNP at AEP-equivalent SEP for dual-eligibles; D-SNP integration partly mitigates the provider-continuity question by aligning Medicare and Medicaid networks.

Outcome. Medicare-primary with CHC Medicaid secondary; mental-health provider continuity is partially operational subject to documented Medicare-behavioral-health-provider participation patterns; clinical pathway depends on D-SNP network architecture. The disability-based Medicare population's specific delivery-side pathway issues sit partly in SD6 Behavioral Health and SUD Delivery and partly in SD7 Specialty Clinical and Cross-Cutting.

Profile 3: Medicare Advantage choice navigation in South/Southwest (MC54 Both/And)

Constituent type: a South/Southwest sub-area PA-3 resident, aged 66, middle-income retiree, not dual-eligible, enrolled in Medicare Advantage at IEP in 2025 following the 65th birthday; now considering plan change at AEP 2026. Selected one of the 66 Philadelphia County non-SNP MA plans — including dental, vision, and OTC benefit allowances not available under Original Medicare with Medigap.

Substantive contribution (MC54 left side). The MA plan delivered as designed — $0 monthly premium beyond Part B (one of the 42 Philadelphia County $0-premium plans); supplemental dental and vision benefits the constituent used; transportation benefit to medical appointments; OTC allowance for over-the-counter medications and personal-care items; care-coordination architecture connecting the constituent with an in-network primary care provider; in-network MOOP cap at approximately $6,858 (Philadelphia County average) — a structural ceiling on out-of-pocket exposure that Original Medicare without Medigap does not provide.

Structural displacement (MC54 right side). Over the first year the constituent encountered several MA structural features that did not surface at enrollment: the plan's provider network restricted access to certain specialty providers used by family members and recommended for specific conditions; prior-authorization requirements delayed initiation of one therapy; the formulary did not include a specific medication the constituent had used pre-Medicare under employer coverage, requiring transition to a formulary alternative. At AEP 2026 the constituent considered returning to Original Medicare with Medigap; PA MEDI counseling clarified that Pennsylvania's lack of state-level guaranteed-issue Medigap protections outside the initial 6-month OEP meant the Medigap return would require medical underwriting; given health-status changes during the MA year, the underwriting outcome was uncertain. The effective choice set narrowed to remaining in the current MA plan, switching to a different MA plan with potentially different network and formulary restrictions, or returning to Original Medicare without Medigap supplementation (accepting Part A and B cost-sharing exposure without supplemental coverage).

MC54 Both/And outcome. The substantive MA choice architecture serves beneficiaries through documented mechanisms (supplemental benefits; care coordination; predictable cost-sharing). The structural displacement is the one-way lock-in created by the interaction of MA enrollment-side flexibility and Medigap return-side underwriting requirement in states without guaranteed-issue protections. Both sides operate simultaneously; neither erases the other.

Conversational note

The Medicare delivery architecture is often described as a federal entitlement that offers simple, comprehensive coverage to anyone who reaches age 65 or qualifies through disability. The structure of the actual delivery experience in PA-3 does not match that description. At every transition point — initial enrollment, plan reselection at AEP, the dual-eligible coordination layer, and the post-Medicare-Advantage Medigap return attempt — the constituent encounters a structural complexity that the entitlement framing does not anticipate, and the consequences fall most heavily on the constituents whose income, language proficiency, cognitive capacity, or social support network is least suited to navigating it.

The single most consequential structural feature of Medicare delivery for PA-3 constituents in Pennsylvania is the asymmetry between Medicare Advantage enrollment and Medicare Advantage exit. A 65-year-old beneficiary in 2026 can enter Medicare Advantage with one telephone call during their Initial Enrollment Period and need not answer a single health question. The same beneficiary, two years later, having developed a chronic condition or experienced a hospitalization, cannot reliably exit Medicare Advantage back to Traditional Medicare with Medigap supplementation in Pennsylvania without going through medical underwriting that may decline coverage or impose substantially higher premiums based on the health-status changes that occurred during the MA enrollment period. The structural lock-in is not a feature of Medicare Advantage itself; it is a feature of the interaction between federal MA enrollment rules and Pennsylvania's lack of a state-level guaranteed-issue Medigap protection. Approximately 17 states address this through annual birthday-rule or anniversary-rule protections; Pennsylvania has considered but not enacted such a provision. Federal House representation has no direct control over Pennsylvania's state Medigap underwriting rules, but federal policy could address the asymmetry through federal guaranteed-issue Medigap return legislation paralleling the IRA's improvement of the Part D out-of-pocket cap structure.

The second feature worth naming explicitly is the IRA Medicare Drug Price Negotiation Program's delivery-side operationalization. The substantive architecture (drug selection, negotiation, maximum fair price establishment) is D2 SD4 Chronic & Non-Communicable Disease territory; the delivery-side operationalization is D21 SD1 territory. For PA-3 beneficiaries using any of the 10 IRA-selected drugs in 2026 (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog/Fiasp), the structural change is concrete: the negotiated price reaches the pharmacy point of sale; the Part D plan covers all 10 selected drugs under the coverage requirement; the $2,100 annual OOP cap operates as a ceiling regardless of the specific drug used. Approximately 9 million Medicare enrollees nationally used these 10 drugs in 2023; the PA-3 share is structurally inferable from PA's approximately 6% share of national Medicare enrollment. Federal House representation has direct advocacy leverage at the appropriation, statutory-protection, and CMS-implementation-guidance layers.

The third feature is the federal-state-local pathway dependency. Original Medicare and Medicare Advantage are federal programs, but the PA-3 constituent's access to Medicare-participating providers, Medigap supplementation, dual-eligible coordination, and Part D pharmacy networks depends on Pennsylvania's regulatory architecture and Philadelphia's local navigation infrastructure. PA MEDI counselor capacity — at 1-800-783-7067 statewide, and at the Philadelphia Corporation for Aging locally — is the operational bottleneck for beneficiary navigation. The capacity is grant-funded under the federal SHIP authority; counselor-to-beneficiary ratios determine how much of the structural complexity each beneficiary is helped to navigate. Federal House representation can engage at the SHIP appropriation layer to expand counselor capacity for the PA-3 beneficiary population.

Geography & representation

Data provenance. PA Medicare enrollment counts, Philadelphia County MA penetration, plan counts, and IRA Part D structural parameters are documented in CMS public data products (CMS State, County, and Contract enrollment files; CMS Part D plan finder; CY 2026 Part D Redesign Program Instructions issued April 7, 2025) plus Connie Health analyses of CMS data plus Kaiser Family Foundation 2024-2026 reporting. The PA Insurance Department Medigap framework and PA MEDI architecture are documented in PA primary sources. Co-Sponsorship Memo 47375 (proposed PA Medigap birthday rule) is documented in the PA General Assembly 2025-2026 Regular Session record. The 10 IRA Round 1 selected drugs and the maximum fair prices effective January 1, 2026 are documented in CMS announcements; Round 2 (15 drugs effective January 1, 2027) maximum fair prices were announced approximately late November 2025; Round 3 selections in early 2026 were affected by the OBBBA orphan-drug exclusion expansion. PA-3-specific Medicare beneficiary counts disaggregated to the four-sub-area resolution are not retrievable from publicly available CMS data products and are flagged for institutional retrieval.

PA-3 statistical profile. Pennsylvania's 2026 total Medicare enrollment is approximately 2,981,142. Pennsylvania's population aged 65+ is approximately 2.6 million (~20% of state total); the PA Medicare-enrolled count exceeds the 65+ population because Medicare enrollment includes the disability-based and ESRD/ALS-based entitled population. Pennsylvania's statewide MA penetration was approximately 57% in 2024; Philadelphia County's MA penetration is approximately 59.89% for 2026, approximately 3 percentage points above the PA statewide rate. Pennsylvania has 334 MA plans available statewide in 2026; Philadelphia County has 66 non-SNP MA plans, 19 D-SNPs, and 7 I-SNPs. The dominant non-SNP plan in Philadelphia County by enrollment is Keystone 65 Basic Rx (HMO) with 13,929 enrollees. Non-SNP MA enrollment in Philadelphia County is approximately 81,754; D-SNP enrollment approximately 62,931; I-SNP enrollment approximately 536 — aggregating to approximately 145,221 Philadelphia County beneficiaries in MA arrangements. The 2026 average MA MOOP in-network for Philadelphia County is approximately $6,858 against the CMS 2026 in-network MA MOOP statutory maximum of $9,250. The average monthly premium for plans charging a premium beyond Part B is approximately $35.26. The stand-alone Part D market in PA offers 12 plans for 2026 with the lowest monthly premium at $6.60. Approximately 22.21% of PA stand-alone Part D enrollees receive Low-Income Subsidy (Extra Help).

Geographic variation.

• North/Northwest Philadelphia Core. Documented higher rates of disability-based Medicare entitlement reflecting working-age disability prevalence linked to documented health disparities (cross-reference D2 SD3 plus cumulative-disadvantage geography findings). Higher dual-eligible concentration. D-SNP enrollment density expected highest in this sub-area structurally.
• West Philadelphia Core. Documented older-population concentration in the longtime Black homeowner population (cross-reference D7 SD1). Anchor-institution medical-provider proximity (Penn, Penn Presbyterian, CHOP, Drexel) — high provider density but documented Medicare-and-Medicaid acceptance variability at the practice level.
• Northwest Philadelphia. Internally heterogeneous; higher-income tracts (Mt. Airy, Chestnut Hill, East Falls) carry established middle-class older population with more capacity for self-navigation; lower-income tracts (Germantown, Stenton, West Oak Lane) approximate North Core patterns. Within-sub-area variance is greater than between-sub-area variance.
• South/Southwest Philadelphia. Documented immigrant population concentration interacts with Medicare eligibility (the 5-year-residency requirement for premium-free Part A) and language-access pathway-breakdown points. Lower per-capita disability-based entitlement; higher language-access counseling demand at PA MEDI counselor capacity.

PA-3-specific Medicare beneficiary distribution by Original-Medicare-versus-MA choice, dual-eligible status, and LIS take-up at four-sub-area resolution is not separately published in CMS public data products and is flagged for institutional retrieval (CMS Office of Minority Health; CMS Chronic Conditions Data Warehouse).

Gap analysis

Seven structural gaps recur across the constituent profiles and the architectural layers above.

G21-SD1-01 — Medicare Advantage one-way structural lock-in absent Pennsylvania state guaranteed-issue Medigap rules (MC54 Both/And PRIMARY). Substantive contribution: Medicare Advantage in Philadelphia County delivers documented benefits — 42 plans at $0 premium beyond Part B; supplemental dental, vision, hearing, transportation, and OTC benefits not available under Original Medicare; in-network MOOP cap averaging $6,858 against the 2026 statutory maximum of $9,250; care coordination; D-SNP integration for dual-eligibles. Structural lock-in: Pennsylvania does not have a state-level annual Medigap birthday rule or anniversary rule. After the one-time 6-month Medigap Open Enrollment Period that follows initial Part B effective date, Pennsylvania Medigap insurers may apply medical underwriting outside the limited federal guaranteed-issue triggers. The asymmetry between federal MA enrollment-side flexibility and Pennsylvania's underwriting-required exit-side creates a one-way structural lock-in: beneficiaries who enroll in MA at IEP cannot reliably return to Traditional Medicare with Medigap supplementation in subsequent years if their health status changes. Proposed PA legislation (Co-Sponsorship Memo 47375) would establish a 60-day birthday-rule window; the bill is not enacted as of May 2026. Representation implication: Federal House representation cannot directly intervene in Pennsylvania's state-level Medigap underwriting rules, but federal policy could address the asymmetry through federal guaranteed-issue Medigap return rights legislation paralleling the IRA's Part D OOP cap improvement.

G21-SD1-02 — IRA Medicare Drug Price Negotiation Program delivery-side operational status. The first 10 IRA-negotiated drug prices became effective January 1, 2026 for Medicare Part D delivery. All Part D plans cover all 10 selected drugs at the negotiated Maximum Fair Price under the IRA coverage requirement. Estimated $1.5 billion annual beneficiary OOP savings and $6 billion annual Medicare program savings nationally; discounts range 38%-79% from 2023 list prices. Trump EO 14273 (April 15, 2025) maintained the program while directing modification proposals; the 2025 budget reconciliation law (OBBBA) broadened the orphan drug exclusion affecting 2028-and-beyond drug selection; 15 drugs selected for 2027 negotiated prices; 15 drugs selected for 2028 (first Part B inclusion). Representation implication: Federal House representation has direct advocacy on IRA appropriation, statutory protection, and CMS implementation guidance; the 2025 reconciliation's orphan-drug-exclusion expansion is a legislative-action trajectory item; CMS implementation guidance under EO 14273 is administrative-engagement territory.

G21-SD1-03 — Provider Medicare assignment and participation gap. Pennsylvania prohibits Medicare excess charges, simplifying the cost calculus for beneficiaries who see Medicare-participating providers. However, providers may opt out of Medicare entirely. PA-3-specific Medicare provider participation rates by specialty (primary care; behavioral health; specialty care) are not retrievable from publicly available data products at SD1. Documented national patterns establish behavioral-health Medicare participation rates are systematically lower than primary-care rates — SD6 Behavioral Health and SUD Delivery owns the behavioral-health-delivery analysis. Representation implication: Federal CMS can address provider participation through Medicare physician fee schedule adjustments and value-based purchasing initiatives.

G21-SD1-04 — Dual-eligible coordination complexity at the Medicare-Medicaid-CHC architecture interface. Pennsylvania's approximately 19 Philadelphia County D-SNPs serve approximately 62,931 dual-eligible beneficiaries in Philadelphia County. D-SNPs provide partial Medicare-Medicaid integration. For dual-eligibles not enrolled in D-SNPs, coordination across Medicare-primary (Original or non-SNP MA) and Community HealthChoices Medicaid-secondary architecture requires navigation across separate plan networks, separate provider participation lists, and separate appeals pathways. The structural coordination burden falls disproportionately on low-income beneficiaries who lack the navigation capacity. Cross-reference D12 SD2 (eligibility-side architecture). Representation implication: Federal CMS has direct authority on D-SNP architecture, Medicare-Medicaid integration program design, and dual-eligible navigation support.

G21-SD1-05 — Part D Low-Income Subsidy (Extra Help) take-up gap. Approximately 22.21% of Pennsylvania stand-alone Part D plan enrollees receive Low-Income Subsidy (Extra Help). National literature documents an LIS take-up gap with eligible-but-not-enrolled populations consistently above 10% of the eligible pool. PA-3-specific LIS take-up rates by sub-area are not disaggregated in public data products. Representation implication: Federal CMS and SSA share LIS administration responsibility; outreach intensity and procedural complexity affect take-up.

G21-SD1-06 — Medicare beneficiary navigation infrastructure capacity gap (PA MEDI / SHIP). PA MEDI operates under PA Department of Aging as Pennsylvania's federally-designated SHIP; central counseling line 1-800-783-7067; local capacity in Philadelphia delivered through Philadelphia Corporation for Aging. The SHIP grant funding from CMS sets statewide counselor capacity. PA-3 beneficiary-to-counselor ratio is not separately documented; structural inference from documented SHIP capacity patterns is that PA MEDI provides counseling reach below what the structural complexity of plan choice warrants — the 66 MA plans plus 12 stand-alone Part D plans plus 10 Medigap lettered plans plus D-SNP and CHC coordination is a navigation problem that exceeds many beneficiaries' independent capacity. Representation implication: Federal House representation has direct advocacy on SHIP appropriation; appropriation increases can directly expand counselor capacity.

G21-SD1-07 — Sub-area data resolution gap. PA-3-specific Medicare beneficiary counts disaggregated by sub-area (North/Northwest Core, West Core, Northwest, South/Southwest) and by Original-Medicare-versus-MA choice, dual-eligible status, and LIS take-up are not separately published in CMS public data products. The four-sub-area resolution gap limits what can be analyzed at the level the rest of D21's architectural analysis operates at. Representation implication: Routine public-data disclosure at the sub-area level would partially close the gap without program reform; the data exist at the Chronic Conditions Data Warehouse and CMS Office of Minority Health but are not consistently published at PA-3 sub-area resolution.

Where this leads

Medicare is the project domain where federal House advocacy maps most directly to PA-3 beneficiary experience — among the most direct mappings in the project's representation framework. Federal CMS regulatory posture, IRA drug-pricing statutory protections, SHIP appropriation, and MA plan oversight legislation are all federal-rep levers. The state-level Medigap underwriting question is outside direct federal House control but is addressable through federal guaranteed-issue Medigap return legislation. The dual-eligible architecture is jointly federal-state but federal CMS has direct authority on the Medicare-side coordination program design.

The next sub-domain — Medicaid Delivery Architecture — analyzes the parallel Medicaid delivery architecture (HealthChoices Physical Health MCO 4-plan Southeast Zone; CHC for dual-eligibles and LTSS-eligible adults) under the OBBBA implementation calendar (Sections 71107 / 71115 / 71117 / 71119 plus Section 71401 Rural Health Transformation Fund; CMS implementation guidance through June 2026 Interim Final Rule). The structural Both/And designation operating at SD2 is MC60 (substantive managed-care architecture plus structural OBBBA fiscal disruption); the SD1 dual-eligible coordination findings carry forward to the SD2 CHC analysis.